Qualigen Therapeutics, Inc.

NasdaqCM QLGN

Qualigen Therapeutics, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.00

Qualigen Therapeutics, Inc. Revenue is USD 0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a -100.00% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Qualigen Therapeutics, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 12.57 M, a 147.64% change year over year.
Qualigen Therapeutics, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 5.07 M, a -3.89% change year over year.
Qualigen Therapeutics, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 5.28 M.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

NasdaqCM: QLGN

Qualigen Therapeutics, Inc.

CEO	Mr. Kevin A. Richardson II
IPO Date	June 23, 2015
Location	United States
Headquarters	2042 Corte Del Nogal
Employees	4
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Key trends

Past 5 years